David Baker
Vorsitzender bei DEVONIAN HEALTH GROUP INC.
Vermögen: 18 $ am 30.04.2024
Aktive Positionen von David Baker
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
GRI BIO, INC. | Direktor/Vorstandsmitglied | - | - |
DEVONIAN HEALTH GROUP INC. | Vorsitzender | 04.12.2023 | - |
Direktor/Vorstandsmitglied | 12.05.2023 | 04.12.2023 | |
Independent Dir/Board Member | 12.05.2023 | 04.12.2023 | |
Philadelphia Education Fund | Vorsitzender | - | - |
Benchworks, Inc.
Benchworks, Inc. Miscellaneous Commercial ServicesCommercial Services Benchworks, Inc. engages in the provision of marketing services. It offers brand development and strategy, creative services, print media and non personal promotion, and event planning and management. The company was founded by Thad L. Bench in 1991 and is headquartered in Chestertown, MD. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von David Baker
Ehemalige bekannte Positionen von David Baker
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
GRI BIOPAR | Comptroller/Controller/Auditor | - | 10.05.2021 |
Direktor/Vorstandsmitglied | 23.10.2020 | 01.05.2023 | |
Vorstandsvorsitzender | 23.08.2019 | 21.04.2023 | |
Finanzdirektor/CFO | - | 10.05.2021 | |
Gründer | 11.01.2018 | 01.05.2023 | |
Präsident | 23.08.2019 | 21.04.2023 | |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | Vorstandsvorsitzender | 31.05.2017 | 01.11.2017 |
Corporate Officer/Principal | 13.01.2014 | 31.05.2017 | |
Präsident | 31.05.2017 | 01.11.2017 | |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Corporate Officer/Principal | 01.04.2004 | 01.12.2013 |
Ausbildung von David Baker
Duke University | Undergraduate Degree |
The Fuqua School of Business | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 8 |
Israel | 2 |
Kanada | 2 |
Operativ
Director/Board Member | 4 |
Chief Executive Officer | 2 |
Corporate Officer/Principal | 2 |
Sektoral
Health Technology | 6 |
Consumer Services | 3 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
GRI BIO, INC. | Health Technology |
DEVONIAN HEALTH GROUP INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | Health Technology |
Philadelphia Education Fund | |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
Vallon Pharmaceuticals, Inc.
Vallon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Vallon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of proprietary biopharmaceutical products. The firm's primary product is Abuse-Deterrent Amphetamine Immediate and its product pipeline includes ADAIR, ADMIR, ADHD, and Narcolepsy. The company was founded by David C. Baker on January 11, 2018 and is headquartered in Philadelphia, PA. | Health Technology |
Benchworks, Inc.
Benchworks, Inc. Miscellaneous Commercial ServicesCommercial Services Benchworks, Inc. engages in the provision of marketing services. It offers brand development and strategy, creative services, print media and non personal promotion, and event planning and management. The company was founded by Thad L. Bench in 1991 and is headquartered in Chestertown, MD. | Commercial Services |
- Börse
- Insiders
- David Baker
- Erfahrung